Q2 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics Inc (NASDAQ:CAPR) – HC Wainwright issued their Q2 2025 EPS estimates for shares of Capricor Therapeutics in a research report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.36) for the quarter. HC Wainwright currently has a “Buy” rating and a $77.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Thursday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $12.86 on Friday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a 50-day moving average of $14.06 and a 200 day moving average of $14.55. The firm has a market capitalization of $584.74 million, a price-to-earnings ratio of -12.13 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently modified their holdings of CAPR. Farallon Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $31,056,000. Vanguard Group Inc. raised its holdings in shares of Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after purchasing an additional 700,243 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $8,693,000. Altium Capital Management LLC raised its holdings in shares of Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after purchasing an additional 429,000 shares in the last quarter. Finally, Black Diamond Financial LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $3,833,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.